Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
North Star
- Development stage
- Phase 3
- Lead developer
- Brookstone
- Administration
- Oral
01
Overview
North Star is an investigational desiccated thyroid extract (DTE) developed by Neuvosyn Laboratories, LLC, and Acella Pharmaceuticals for the treatment of primary hypothyroidism. It functions as a hormone replacement therapy, supplying both T4 (thyroxine) and T3 (triiodothyronine) to restore thyroid hormone levels. This aims to regulate metabolism, energy production, heart function, and brain health, offering an alternative to synthetic levothyroxine for patients who may not achieve full restoration with current treatments.
- Other names
- Desiccated Thyroid ExtractDTE
02
Targets
THR (Thyroid hormone receptor)
Beyond the preview
Go deeper on North Star.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on North Star.